ImmunogenX acquires Alvine Pharmaceuticals' assets
Clinical-stage company ImmunogenX has acquired the assets of Alvine Pharmaceuticals, which develops biologics to target autoimmune / inflammatory diseases.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: Autoimmune Disease | Pharmaceuticals